Navigation Links
Early Diagnosis and Treatment the Focus of International Dialogue on Primary Immunodeficiency Disease
Date:4/20/2011

KING OF PRUSSIA, Pa., April 20, 2011 /PRNewswire/ -- Thought leaders from the medical, scientific and patient advocacy communities gathered in New York and London for CSL Behring's Key Issues Dialogue–Immunoglobulin to examine challenges facing patients with primary immunodeficiencies. They found common ground between the US and Europe on access-to-care issues such as early diagnosis and treatment of primary immunodeficiency disease (PID) and explored possible ways of improving patient care.

(Logo: http://photos.prnewswire.com/prnh/20100914/PH63692LOGO)

The Think Zebra! campaign from the Immune Deficiency Foundation (IDF) put the challenge of early diagnosis in perspective. "In medical school, physicians are taught that when you hear hoof beats, think horses," Marcia Boyle, Dialogue participant and president and co-founder of IDF said.  "In other words, think of the most usual cause of the most usual diagnosis. Immunologists are taught when they hear hoof beats to think zebras. Look for the unusual."

The participants examined barriers to accessing immunoglobulin (Ig) therapy, which is available through subcutaneous and intravenous dosing, including challenges by some insurance plans that impede patient care. "Specialists cannot see a patient initially and then have the remaining care provided by a doctor closer to the patient's home and still be covered by insurance," said Dr. Richard A. Lewis, Professor and Associate Chairman of Neurology, Wayne State University School of Medicine.

Medicare and insurance companies sometimes determine the location of care based on criteria that do not consider the patient's best interests and that are not necessarily the most cost-effective option, according to Dr. John W. Sleasman, Robert A. Good Professor and Chief-Division of Allergy, Immunology and Rheumatology, Pediatrics Department, University of South Florida.  "The patient is required by Medicare to travel two hours by ambulance from his home to a hospital where he is administered intravenous Ig," Dr. Sleasman said about a patient in his seventies with common variable immunodeficiency. "It would be much more convenient and less costly to administer it in his home."

The problem has been further compounded by cuts to healthcare benefits. As a result, patients are experiencing longer intervals between Ig treatments and in some cases never get back to that point where they left off when they were getting infusions on a regular basis. "They [patients] go downhill, and they then end up with health changes that require treatment they didn't need before," Dr. Sleasman said.

Another challenge involves rigid guidelines for managing patients, particularly with respect to dosage. "You need guidelines but when they're too specific, insurance companies can really misuse them," Boyle said. Dr. Lewis added that in Europe, discussions about dosage restrictions are linked to the development of health technology assessments (HTA) which factor in dosage, efficacy and cost. "We have to be careful in the area of HTAs and provide data in a timely and effective way," Dr. Lewis said.

The participants agreed that Ig patients often have dramatically different needs in terms of dosing, formulation and methods of administration as they grow from infancy to adulthood. It is important for the makers of biotherapies used to treat PID to help manage patients' needs throughout their lifecycles, just as they manage the lifecycle of the products in their portfolio. Areas of common ground between the US and Europe were identified including a universal emphasis on sharing information to ensure that patients receive optimal care. Boyle said an IDF Internet survey found that patients who are connected to a patient organization receive better care than those that are not.

About CSL Behring

CSL Behring is a leader in the plasma protein therapeutics industry. Committed to saving lives and improving the quality of life for people with rare and serious diseases, the company manufactures and markets a range of plasma-derived and recombinant therapies worldwide.

CSL Behring therapies are indicated for the treatment of coagulation disorders including hemophilia and von Willebrand disease, primary immune deficiencies, hereditary angioedema and inherited respiratory disease. The company's products are also used in cardiac surgery, organ transplantation, burn treatment and to prevent hemolytic diseases in newborns.

CSL Behring operates one of the world's largest plasma collection networks, CSL Plasma. CSL Behring is a subsidiary of CSL Limited (ASX: CSL), a biopharmaceutical company headquartered in Melbourne, Australia. For more information, visit www.cslbehring.com.

Contact:
Chris Florentz
CSL Behring
610-878-4316
Christopher.Florentz@cslbehring.com


'/>"/>
SOURCE CSL Behring
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Chiltern Early Phase: Fully Integrated and Business Ready
2. Early-Bird Registration Ends this Week for 10th Annual Quality Excellence Conference: How Process Improvement Leaders Produce Profits in Recessions
3. The Lilly TB Drug Discovery Initiative Begins Work on New Compounds to Fill Early-Stage TB Drug Pipeline
4. Update: The Lilly TB Drug Discovery Initiative Begins Work on New Compounds to Fill Early-Stage TB Drug Pipeline
5. Early-Bird Pricing Ends Soon for MichBio Expo Attendees and Exhibitors; Award Nominations Due Nov. 1
6. BSP Signs Agreement With CMP Trading for Distribution of HyperQ(TM) Stress System, for Early Detection of Ischemic Heart Disease, in South Korea
7. RVX-208 Exploratory Study Illustrates Early Potential for Alzheimers Disease
8. MichBio Expo Draws Nearly 500 Professionals; Career Day Raises Profile
9. Cryoablation of Early Invasive Ductal Breast Cancer With MRI Confirmation Shows Promising Clinical Benefits, According to Study Presented at RSNA
10. SMU chemist wins NSF early career award
11. Carbon nanotube avalanche process nearly doubles current
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/16/2017)... MENLO PARK, Calif. and ... -- Longitude Capital, a private investment firm focused on ... today announced the promotion of Josh Richardson ... Richardson focuses on investments in biotechnology companies.  He ... and has played important roles in Longitude,s investments ...
(Date:2/16/2017)... , Feb. 16, 2017 Research ... "Synthetic Biology: Global Markets" report to their offering. ... ... (synthetic genes, biobrick parts, delivery plasmids, chassis organisms, synthetic ... and assembly, genome editing, bioinformatics and specialty media) and ...
(Date:2/16/2017)... February 16, 2017 Patient ... of innovative telemedicine application, new and leading edge ... experiencing a boom worldwide. The healthcare sector as ... technologies, services and new therapies for companies such ... RHT), Cellectar Biosciences, Inc. (NASDAQ: CLRB ...
(Date:2/16/2017)...  Champions Oncology, Inc. (NASDAQ: CSBR ), ... advanced technology solutions and products to personalize the development ... of new cohorts of PDX models to their existing ... Champions, product line in hepatocellular cancer, breast cancer, castrate ... non-small cell lung cancer (including EGFR mutation; ALK/ROS1 positive) ...
Breaking Biology Technology:
(Date:2/7/2017)... 2017   MedNet Solutions , an innovative SaaS-based ... clinical research, is pleased to announce that the latest ... highly flexible and award winning eClinical solution, is now ... is a proven Software-as-a-Service (SaaS) clinical research technology ... but also delivers an entire suite of eClinical tools ...
(Date:2/3/2017)... A new independent identity strategy consultancy firm ... . Designed to fill a critical niche in technical ... partners Mark Crego and Janice Kephart ... identity expertise that span federal governments, the 9/11 Commission, ... combined expertise has a common theme born from a ...
(Date:1/31/2017)... Mass. , Jan. 31, 2017  Spero ... novel therapies for the treatment of bacterial infections, ... set of antibacterial candidates from Pro Bono Bio ... increased prevalence of multi-drug resistant forms of Gram-negative ... Cantab Anti Infectives Ltd, a PBB group company. ...
Breaking Biology News(10 mins):